UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: December 31, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38355 Nemaura Medical Inc. (Exact name of registrant as specified in its charter) NEVADA 46-5027260 (State or other jurisdiction ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2021 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38355 Nemaura Medical Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2021 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38355 Nemaura Medical Inc. (Exact name of registrant as specified in its charter) NEVADA 46-5027260 (State or other jurisdiction of i ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ————— FORM 10-K —————— ý ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 NEMAURA MEDICAL INC. (Exact name of registrant as specified in its charter) For the transition period from _________ to _________ Commission File Number 001-38355 Nevada 46-5027260 (State or othe ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: December 31, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38355 Nemaura Medical Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation o ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2020 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38355 Nemaura Medical Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or org ...

市场前景 - 全球2型糖尿病市场预计到2025年将达到587亿美元[12] - 全球数字糖尿病市场预计到2026年将超过160亿美元[12] - 英国糖尿病市场预计到2025年将达到587亿美元[45] - 美国糖尿病患者中，只有2.6%的2500万名患者使用连续血糖监测(CGM)设备[45] - 美国的CGM使用在2018年增长了117%[45] - Nemaura预计在英国的潜在用户可达20万人[45] 产品与技术 - Nemaura的非侵入性连续血糖监测器SugarBEAT®已获得CE认证，预计在2020年第四季度开始在英国、爱尔兰和德国销售[13] - Nemaura的proBEAT产品预计将在2020年第四季度在美国推出，毛利率可达75%[13] - Nemaura的SugarBEAT®传感器每五分钟记录一次血糖水平，提供实时数据[19] - Nemaura的产品管道包括针对II型糖尿病患者和前糖尿病患者的可穿戴健康技术[53] - Nemaura计划在未来18个月内申请多项新专利[66] 商业策略 - Nemaura计划在未来五年内主导可穿戴市场，目标是通过传感器和数字医疗平台实现自我管理[6] - Nemaura的商业策略包括基于订阅的服务，计划在2020年底上线[37] - Nemaura的目标是到2020年底实现来自美国、英国和德国的收入，毛利率可达75%[69] 财务状况 - 截至2020年8月底，Nemaura的现金约为1800万美元，季度现金消耗率约为100万美元[69] - Nemaura的数字健康投资在2019年达到了75亿美元[33] 用户数据 - 英国目前约有350万糖尿病患者和700万前糖尿病患者[42]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 57 West 57th Street Manhattan, NY 10019 þ QUARTERLY REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2020 or ¨ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ————— FORM 10-K —————— ý ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to _________ Commission File Number 001-38355 NEMAURA MEDICAL INC. (Exact name of registrant as specified in its charter) Nevada 46-5027260 (State or othe ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) þ QUARTERLY REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: December 31, 2019 or ¨ TRANSITION REPORT UNDER SECTION13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission File Number: _______________________ Nemaura Medical Inc. (Exact name of small business issuer as specified in its charter) (State or other j ...